subject: Research to develop new drugs CRO committed to building the industry chain - new drugs, research - pharmaceutical industry [print this page] With the degree of specialization, research and development costs rising, New Drugs The study is no longer able to rely solely on completion of a unit, but needs joint efforts of multiple organizations. Therefore, the contract research organizations (CRO) Baotuan charting trends are becoming evident. Birth in this trend, the opening in October 22 the twelfth biomedical industry development forum, the Beijing Union CRO organizations?? China Biotechnology Outsourcing Services Alliance (ABO)'s "one-stop -service "concept and" form a complete industrial chain, and multinational dialogue, participation in the global division of labor ", the sing R & D services through the promotion of innovation and a prelude to the biomedical industry. China Opportunities For efficiency, reduce costs and risk considerations, system Pharmaceutical companies Industry has become increasingly part of the development process outsourcing part or all of the links to outside research organizations with expertise or business?? CRO. Today, CRO development in the global pharmaceutical industry play an increasingly important role, and its services starting from the compound screening, safety evaluation until after the listing of new drugs, involving various aspects of the entire drug development. The service type corresponding to differentiate into R & D engineering services, R & D services and R & D results of services in Class 3. CRO business with the rapid development of a biomedical research and development covering the whole process of new industry?? Developed the concept of service came into being. , According to data from market consulting firm, the global biomedical R & D outsourcing market was worth about 20 billion U.S. dollars, and the rate of 16% a year growth in 2010 will reach 36 billion U.S. dollars in size. In this emerging industry, Asia, China and India impressive. India are familiar with international drug registration regulations, the talent, the same cost advantage, therefore, India has been slightly better. But in August 2008 PricewaterhouseCoopers recently released "Asia Pharmaceutical R & D developments," the report states: based on cost, risk and three indicators to assess market opportunities, China has surpassed India to become Asia's first choice for R & D outsourcing. According to the report of PricewaterhouseCoopers, 2008, China's pharmaceutical R & D outsourcing market is about 260 million U.S. dollars, is expected to grow by 2010 to 4.3 million. Demand in the global R & D to stimulate the transfer, the local CRO companies quickly emerged. In just five to six years time, China has emerged more than 400 CRO business. Services have expanded to the pre-clinical studies, clinical studies, compound screening, Preparation Research, etc. segments. Zhongguancun in Beijing, Shanghai Zhangjiang Hi-Tech Park, both domestic CRO firms are concentrated, bio-technology in China gradually Outsourcing Alliance (ABO), Zhongguancun CRO alliance, Pudong New Area League of biomedical R & D outsourcing services, biomedical research and development outsourcing CRO's Union Commission, and gradually developed into the backbone of China's CRO. Beijing's choice As the Roche Research (China) Limited said Chen Li, Chief Scientific Officer, Roche Research Center of China is a developing network management, from the group composed of several different fields, including biological, chemical, clinical and integrated of the team, they belong to different companies. In fact, many multinational companies through various modes of cooperation, with China a number of universities, research institutions, research companies to carry out the work of all sectors of drug development. Chen Li, said, R & D outsourcing need to consider the CRO personnel, capacity, technology and external resources. Amgen's vice president of R & D NahedAhmed said that the cost to consider when outsourcing, quality and innovation. If an organization can integrate all aspects of R & D chain resources, negotiations with multinational companies can have more chips. Drug development is a high risk industry, with competition becoming increasingly fierce, and countries become increasingly concerned about drug safety, the ultimate test of market appeal is not only cost advantages.
Research to develop new drugs CRO committed to building the industry chain - new drugs, research - pharmaceutical industry
